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Introduction
Interleukin-1b (IL-1b) is a basic mediator of cryopyrin-
associated periodic syndromes (CAPS). In this respect an
experience of the use of IL-1 inhibitors has been gained in
patients with CAPS. Canakinumab was approved by FDA
and EMEA in 2009 and registered in the Russian Federa-
tion in 2011 for treatment of CAPS. Canakinumab is
shown to have high efficiency and good tolerability in
patients with CAPS.
Objectives
To present an experience of use of canakinumab IL-1
inhibitor in children with CAPS in Russia.
Methods
The study includes 4 patients with CAPS: two patients
with Muckle-Wells syndromes and two patients with
CINCA/NOMID syndrome including three girls (3.5, 5.5
and 8 years old) and a boy (17 years old). 1 female patient
with MWS received glucocorticoids in a dose of 0.1 mg/kg
and other patients received NSAID. All patients passed
molecular genetic test to find NLRP3(CIAS1) gene muta-
tion. Two patients with MWS had pThr436Ile and
pThr438Ile mutations and two patients with CINCA/
NOMID were negative. Canakinumab was administered in
a dose of 4 mg/kg for body weight under 15 kg or 2 mg/
kg for body weight over 15 kg and injected subcutaneously
every 8 weeks. By now, two patients have received 4 injec-
tions (32 weeks of observation) and two patients have
received 3 injections (24 weeks of observation).
Results
All patients developed significant clinical improvement:
recovery of well-being, relief of fever and rash, reduce in
the level of acute phase markers. The effect is stable
during the whole follow-up period. This allowed to
discontinue glucocorticoid therapy in a female patient
with MWS at all. No adverse effects were observed in any
patients.
Conclusion
An experience of the use of canakinumab in patients with
CAPS has shown high efficiency and good tolerability of
the drug. Decrease in acute phase markers was appeared
to be slower in patients with CINCA/NOMID syndrome
as the most severe CAPS form.
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